Opendata, web and dolomites

safenolaTiCancerDrug SIGNED

Highly and Widely Effective, Water Stable, and Non Toxic Titanium-Phenolato-based Anticancer Chemotherapy

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 safenolaTiCancerDrug project word cloud

Explore the words cloud of the safenolaTiCancerDrug project. It provides you a very rough idea of what is the project "safenolaTiCancerDrug" about.

complexes    varying    companies    experiments    nih    neurotoxicities    cancer    grant    mechanistic    attractive    alternative    clinical    pt    vivo    absorption    entities    formulation    combination    ti    treatment    resistance    vitro    icp    irreversible    metal    concentrations    excretion    made    weeks    water    stg    suffers    clinic    nevertheless    parent    cosmetics    cog    followed    panel    occurred    limited    erc    animal    pharmacokinetic    compound    interaction    lines    welfare    metallodrug    drugs    stable    nephro    treatments    dioxide    employed    chemotherapy    murine    ms    pharmaceutical    generally    toxicity    human    cells    cisplatin    hampered    permitted    ongoing    nci    society    substantially    toxic    doses    mice    severe    dissociation    shown    animals    material    immediately    food    significantly    decomposition    line    mortality    models    toward    enter    titanium    trials    found    pi    therapeutic    rapid    types    bio    final    safe    sights    herein   

Project "safenolaTiCancerDrug" data sheet

The following table provides information about the project.

Coordinator
THE HEBREW UNIVERSITY OF JERUSALEM 

Organization address
address: EDMOND J SAFRA CAMPUS GIVAT RAM
city: JERUSALEM
postcode: 91904
website: www.huji.ac.il

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Israel [IL]
 Total cost 150˙000 €
 EC max contribution 150˙000 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2017-PoC
 Funding Scheme ERC-POC
 Starting year 2017
 Duration (year-month-day) from 2017-11-01   to  2019-04-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    THE HEBREW UNIVERSITY OF JERUSALEM IL (JERUSALEM) coordinator 150˙000.00

Map

 Project objective

Chemotherapy is the most common line of treatment for various cancer types, but it generally suffers from severe side effects. Cisplatin is a highly effective metallodrug employed in the clinic, limited by severe and irreversible nephro- and neurotoxicities and resistance development. Therefore, developing highly and widely effective chemotherapy that is non- or substantially less- toxic should impact immediately and significantly the welfare of society. The titanium metal is an attractive Pt alternative, as it is bio-friendly and non-toxic. Titanium dioxide, the final decomposition product of Ti complexes in water, is a safe material often found in food and cosmetics. Nevertheless, the rapid dissociation of past Ti complexes in water has hampered their development into drugs. Under an ERC-StG grant followed by an ERC-CoG grant, the PI has developed Ti(IV) complexes that are stable for weeks in water, with high in vitro activity toward numerous cells (also established on the NCI-60 panel of the NIH) and in vivo toward murine and human models with no clinical sights of toxicity in treated mice at effective doses, where mortality occurred in control animals treated with cisplatin at similar doses. Pharmaceutical entities have shown specific interest in taking the proposed compound 1 into clinical trials phase I. Some experiments are still required before an agreement can be made, as proposed herein. Through the parent ERC-CoG, mechanistic analyses are ongoing, but no animal studies are permitted. Thus, through the proposed study: (a) pharmacokinetic studies on compound 1 by ICP-MS will determine absorption, bio-distribution, and excretion; (b) In vivo studies of different models and with varying concentrations and formulation types will determine the therapeutic potential; (c) iv vivo combination studies will identify possible lines of treatments. These studies should promote the interaction with pharmaceutical companies to enable compound 1 to enter clinical trials.

 Publications

year authors and title journal last update
List of publications.
2018 Nitzan Ganot, Ori Braitbard, Asaad Gammal, Joseph Tam, Jacob Hochman, Edit Y. Tshuva
In Vivo AnticancerActivityof aNontoxicInertPhenolatoTitaniumComplex:High Efficacyon SolidTumorsAloneand CombinedwithPlatinumDrugs
published pages: , ISSN: 1860-7187, DOI: 10.1002/cmdc.201800551
ChemMedChem 2019-08-30

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SAFENOLATICANCERDRUG" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "SAFENOLATICANCERDRUG" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

InsideChromatin (2019)

Towards Realistic Modelling of Nucleosome Organization Inside Functional Chromatin Domains

Read More  

PROGRESS (2019)

The Enemy of the Good: Towards a Theory of Moral Progress

Read More  

SuperH (2019)

Discovery and Characterization of Hydrogen-Based High-Temperature Superconductors

Read More